Formulary Watch |

All News - Page 22

FTC Targets Two GPOs in PBM Investigation
FTC Targets Two GPOs in PBM Investigation
FTC Targets Two GPOs in PBM Investigation
May 18, 2023
The compulsory orders will require the GPOs, which negotiate drug rebates on behalf of other PBMs, to provide information and records on their business practices.
Specialty Drugs: Higher Patient Cost Sharing and Prior Auths Linked to Abandoned Meds, Treatment Delays
Specialty Drugs: Higher Patient Cost Sharing and Prior Auths Linked to Abandoned Meds, Treatment Delays
Specialty Drugs: Higher Patient Cost Sharing and Prior Auths Linked to Abandoned Meds, Treatment Delays
May 17, 2023
But higher costs for cancer drugs did not influence some common measures of adherence, such as medication possession ratio and proportion of days. The researchers believe that cancer patients may be more likely to adhere to medication regimen, regardless of price, because the drugs are critical for survival.
Dual Steroid Treatment Adds Benefit in Septic Shock, Study Finds
Dual Steroid Treatment Adds Benefit in Septic Shock, Study Finds
Dual Steroid Treatment Adds Benefit in Septic Shock, Study Finds
May 17, 2023
Researchers found a significant decrease in mortality or discharge to hospice with the hydrocortisone-fludrocortisone combination versus hydrocortisone alone in septic shock cases.
FDA Fast Tracks CAR-T Lymphoma Med, Atrial Fibrillation Treatment
FDA Fast Tracks CAR-T Lymphoma Med, Atrial Fibrillation Treatment
FDA Fast Tracks CAR-T Lymphoma Med, Atrial Fibrillation Treatment
May 16, 2023
The atrial fibrillation drug, asundexian, may provide protection from thrombotic events without a corresponding increase in bleeding risk.
PBMs Face New Criticism From Old and New Foes
PBMs Face New Criticism From Old and New Foes
PBMs Face New Criticism From Old and New Foes
May 16, 2023
The National Community Pharmacists Association now has plenty of allies in its fight with the pharmacy benefit managers.
Brexpiprazole Approved as First Drug for Agitation Related to Dementia in Adults with Alzheimer’s Disease
Brexpiprazole Approved as First Drug for Agitation Related to Dementia in Adults with Alzheimer’s Disease
Brexpiprazole Approved as First Drug for Agitation Related to Dementia in Adults with Alzheimer’s Disease
May 12, 2023
The FDA approved Rexulti (brexpiprazole) for Alzheimer’s-related agitation based on the findings of two clinical trials.
New Fabry Disease Treatment Enters Lucrative Market
New Fabry Disease Treatment Enters Lucrative Market
New Fabry Disease Treatment Enters Lucrative Market
May 11, 2023
A wholesale acquisition cost (WAC) for Elfabrio will be announced once it is available in a few weeks.
Rollercoaster of Hospital COVID Drug Spending Continued in 2022
Rollercoaster of Hospital COVID Drug Spending Continued in 2022
Rollercoaster of Hospital COVID Drug Spending Continued in 2022
May 10, 2023
Using a national database, data on medication purchases was collected, along with factors that may have influenced expenditures, such as new therapy availability, patent expirations, policy changes, and legislation.
FDA Okays First-in-Class Eye Spray
FDA Okays First-in-Class Eye Spray
FDA Okays First-in-Class Eye Spray
May 10, 2023
Treatment will benefit millions”of patients, says Eyenovia, the company that developed the product.
Analyzing Cost-effectiveness Thresholds Over Time
Analyzing Cost-effectiveness Thresholds Over Time
Analyzing Cost-effectiveness Thresholds Over Time
May 5, 2023
Cancer-related cost-effective analyses (CEA) referenced higher thresholds than non-cancer-related CEAs, which may suggest interventions for diseases associated with greater mortality and morbidity warrant higher thresholds.
GSK’s Arexvy is First RSV Vaccine Approved for Older Adults
GSK’s Arexvy is First RSV Vaccine Approved for Older Adults
GSK’s Arexvy is First RSV Vaccine Approved for Older Adults
May 4, 2023
In June, the Advisory Committee on Immunization Practices (ACIP) will make recommendations on the appropriate use of the vaccine in the U.S.
Two FDA Approvals for Expanded Pediatric Indications
Two FDA Approvals for Expanded Pediatric Indications
Two FDA Approvals for Expanded Pediatric Indications
May 3, 2023
Cystic fibrosis drug Trikafta gets expanded indication for children ages 2-5.
Avadel Says New Narcolepsy Med Will be Priced Competitively
Avadel Says New Narcolepsy Med Will be Priced Competitively
Avadel Says New Narcolepsy Med Will be Priced Competitively
May 2, 2023
Despite having a highly differentiated clinical value proposition compared to branded, twice-nightly oxybates, Avadel is pricing Lumryz at $64.67 per gram or around $177,034 annually, which is on par with twice-nightly oxybate products that require chronic, middle-of-the-night awakening.
Patients Often Lose in the Battle between Pharma and PBMs
Patients Often Lose in the Battle between Pharma and PBMs
Patients Often Lose in the Battle between Pharma and PBMs
May 2, 2023
Over the last five years, both PBMs and drug manufacturers have implemented restrictions that put more of the costs for specialty medications on patients.
FDA Clears Two Schizophrenia Meds
FDA Clears Two Schizophrenia Meds
FDA Clears Two Schizophrenia Meds
May 1, 2023
Uzedy’s wholesale acquisition cost (WAC) ranges from $1,232 to $3,080 per month.
FDA Approves First Fecal Microbiota Pill for Recurrent C. diff Infection
FDA Approves First Fecal Microbiota Pill for Recurrent C. diff Infection
FDA Approves First Fecal Microbiota Pill for Recurrent C. diff Infection
April 28, 2023
CDI is a leading cause of infections acquired in healthcare settings, including hospitals and nursing homes. After recovering, individuals may get the infection again, and the risk of recurrence increases with each infection.
FDA OKs First-of-its-Kind Treatment for Rare Form of ALS
FDA OKs First-of-its-Kind Treatment for Rare Form of ALS
FDA OKs First-of-its-Kind Treatment for Rare Form of ALS
April 27, 2023
The list price for Qalsody, the first and only approved treatment to target a genetic cause of ALS, may prove to be controversial.
54% of Top-Selling Medicare Drugs Rated as Low-Benefit, Study Finds
54% of Top-Selling Medicare Drugs Rated as Low-Benefit, Study Finds
54% of Top-Selling Medicare Drugs Rated as Low-Benefit, Study Finds
April 26, 2023
The study found that Medicare patients used low-benefit options more frequently than high-benefit options.
Hospital Group Assails AHIP’s Drug Price Report
Hospital Group Assails AHIP’s Drug Price Report
Hospital Group Assails AHIP’s Drug Price Report
April 25, 2023
The American Hospital Association said the health insurers' report on drug prices, which highlights the higher prices charged by hospitals, is “a blatant attempt to deflect from the obvious — insurance companies continue to raise premiums for their enrollees and employer clients while pocketing billions in profit.”
AbbVie Snags New Chronic Migraine Indication for Qulipta
AbbVie Snags New Chronic Migraine Indication for Qulipta
AbbVie Snags New Chronic Migraine Indication for Qulipta
April 24, 2023
Qulipta (atogepant) produced $158 million last year in net revenues in the U.S. as a preventive agent for episodic migraines.
FDA Requires New Warnings For Prescription Opioids in Another Step to Prevent Overdoses
FDA Requires New Warnings For Prescription Opioids in Another Step to Prevent Overdoses
FDA Requires New Warnings For Prescription Opioids in Another Step to Prevent Overdoses
April 21, 2023
One of the warnings regard the risk of opioid-induced hyperalgesia, a condition associated with taking opioids that causes an increase in pain or an increased sensitivity to pain.
Express Scripts Expands Independent Pharmacy in Rural Healthcare
Express Scripts Expands Independent Pharmacy in Rural Healthcare
Express Scripts Expands Independent Pharmacy in Rural Healthcare
April 20, 2023
The expansion offers increased reimbursement opportunities and additional care services to rural independent pharmacies. In addition, it creates an Independent Pharmacy Advisory Committee to expand the role of rural, suburban and urban pharmacies in the healthcare system.
FDA Approves Omisirge to Reduce Infection Risk in Blood Cancer Patients Undergoing Stem Cell Transplant
FDA Approves Omisirge to Reduce Infection Risk in Blood Cancer Patients Undergoing Stem Cell Transplant
FDA Approves Omisirge to Reduce Infection Risk in Blood Cancer Patients Undergoing Stem Cell Transplant
April 19, 2023
Omisirge is a stem cell therapy that helps the body recover more quickly from cancer treatments that kill normal blood cells along with blood cancer cells, thus lowering the risk of infection.
FDA Clears Rizafilm to Treat Acute Migraine
FDA Clears Rizafilm to Treat Acute Migraine
FDA Clears Rizafilm to Treat Acute Migraine
April 19, 2023
The film version may be well-suited for many patients who have migraine-related nausea, says the president of the company that developed the medication.
  FDA Declines to Approve Lilly’s Ulcerative Colitis Drug
  FDA Declines to Approve Lilly’s Ulcerative Colitis Drug
FDA Declines to Approve Lilly’s Ulcerative Colitis Drug
April 17, 2023
The FDA cited issues related to the proposed manufacturing of the drug, mirikizumab. Lilly expressed confidence that they could be corrected.
HyQvia Receives Expanded FDA Approval for Pediatric Primary Immunodeficiency
HyQvia Receives Expanded FDA Approval for Pediatric Primary Immunodeficiency
HyQvia Receives Expanded FDA Approval for Pediatric Primary Immunodeficiency
April 14, 2023
HyQvia is the first FDA-approved treatment for primary immunodeficiency (PI) available as a once-a-month subcutaneous injection. Other treatments for PI, while similarly effective, present a greater burden to patients, often requiring more frequent injections or more invasive routes of administration
New Express Scripts Programs Aim to Boost Affordability, Transparency
New Express Scripts Programs Aim to Boost Affordability, Transparency
New Express Scripts Programs Aim to Boost Affordability, Transparency
April 13, 2023
Through Express Scripts’ new Copay Assurance plan, consumers will have lower out-of-pocket costs because of caps on prescription drugs: $5 for generics, $25 for preferred brand drugs, and $45 for preferred specialty brand drugs.
U.S. Payers May Find Tirzepatide Costs Acceptable Given the Treatment Benefits in Patients with Type 2 Diabetes
U.S. Payers May Find Tirzepatide Costs Acceptable Given the Treatment Benefits in Patients with Type 2 Diabetes
U.S. Payers May Find Tirzepatide Costs Acceptable Given the Treatment Benefits in Patients with Type 2 Diabetes
April 12, 2023
Tirzepatide was associated with a greater reduction in hemoglobin A1c and body weight versus semaglutide. Though, with a current list price of $1,023 for a one-month supply of tirzepatide (Mounjaro; Lilly), is it worth it?
AbbVie Withdraws Two Blood Cancer Indications From Imbruvica
AbbVie Withdraws Two Blood Cancer Indications From Imbruvica
AbbVie Withdraws Two Blood Cancer Indications From Imbruvica
April 11, 2023
Other indications for the blockbuster cancer mediation are not affected.
Healthcare Groups, Legislators Slam Texas Mifepristone Ruling
Healthcare Groups, Legislators Slam Texas Mifepristone Ruling
Healthcare Groups, Legislators Slam Texas Mifepristone Ruling
April 10, 2023
This case and a case in Washington state are likely to be appealed to the Supreme Court.
© 2024 MJH Life Sciences

All rights reserved.